Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

64.13USD
15 Dec 2017
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$64.14
Open
$64.08
Day's High
$65.29
Day's Low
$63.02
Volume
860,874
Avg. Vol
458,283
52-wk High
$99.45
52-wk Low
$35.99

Latest Key Developments (Source: Significant Developments)

Clovis Oncology reports Q3 adjusted shr loss of $1.24
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Clovis Oncology Inc -:CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS.Q3 ADJUSTED LOSS PER SHARE $1.24 EXCLUDING ITEMS.Q3 LOSS PER SHARE $1.24.Q3 EARNINGS PER SHARE VIEW $-1.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet
Wednesday, 13 Sep 2017 06:00am EDT 

Sept 13 (Reuters) - Clovis Oncology Inc :Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet.Study successfully achieved primary, key secondary and exploratory endpoints​.Plans to submit supplemental new drug application in U.S. for maintenance treatment indication in ovarian cancer by end of Oct 2017​.In early 2018, plans to file MAA in Europe for maintenance treatment indication upon receipt of potential approval for treatment indication​.  Full Article

Clovis Oncology Q2 loss per share $3.88
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Clovis Oncology Inc ::Clovis Oncology announces second quarter 2017 operating results.Q2 loss per share $3.88.Q2 earnings per share view $-2.13 -- Thomson Reuters I/B/E/S.  Full Article

Bristol-Myers, Clovis Oncology announce broad clinical collaboration
Monday, 31 Jul 2017 06:59am EDT 

July 31 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Clovis Oncology announce a broad clinical collaboration to evaluate combination of opdivo (nivolumab) and rubraca (rucaparib) in phase 2 and pivotal phase 3 clinical trials in multiple tumor types.Bristol-Myers Squibb Co says specific terms of agreement were not disclosed.Bristol-Myers Squibb Co - specific terms of agreement were not disclosed.Bristol-Myers Squibb Co - ‍all three studies are expected to begin before end of 2017​.Bristol-Myers Squibb - phase 2 trial to evaluate opdivo in combination with rubraca, other compounds in metastatic castration-resistant prostate cancer.Bristol-Myers Squibb Co says planned multi-arm clinical trials will be conducted in U.S., Europe, and possibly additional countries.Bristol-Myers Squibb - phase 3 trials planned for 2017 will evaluate rubraca in combination with opdivo, rubraca as monotherapy, & opdivo as monotherapy.Bristol-Myers Squibb Co - ‍clovis will be study sponsor and conducting party for ovarian cancer study​.Bristol-Myers Squibb - collaboration will also include phase 2 study to evaluate safety and efficacy of opdivo in combination with rubraca.  Full Article

Clovis Oncology announces upsizing and pricing of public offering
Tuesday, 20 Jun 2017 07:06pm EDT 

June 20 (Reuters) - Clovis Oncology Inc -:Clovis Oncology announces upsizing and pricing of public offering of common stock.Size of offering was upsized from $250 million to $300 million.Clovis Oncology Inc says priced underwritten public offering of 3.4 million shares of its common stock at $88.00 per share.  Full Article

Clovis Oncology announces proposed offering of common stock
Monday, 19 Jun 2017 04:01pm EDT 

June 19 (Reuters) - Clovis Oncology Inc ::Clovis Oncology announces proposed offering of common stock.Clovis Oncology Inc - commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million.Clovis Oncology Inc - to use net proceeds of offering for sales and marketing expenses associated with Rubraca in United States, among others.  Full Article

Clovis entered settlement agreement for purported class action litigation
Monday, 19 Jun 2017 06:17am EDT 

June 19 (Reuters) - Clovis Oncology Inc : :Clovis Oncology -on June 18,entered stipulation, agreement of settlement intended to settle purported class action litigation, Medina V. Clovis Oncology.Clovis Oncology -under terms of proposed settlement, putative class of purchasers of co's securities to receive total consideration of about $142.0 million.Clovis Oncology Inc - cash portion of proposed settlement is expected to be funded by company's insurance carriers - SEC filing.Clovis Oncology - in connection with proposed settlement, expects to record charge to earnings in Q2 2017 in amount of about $142.0 million.Clovis Oncology Inc - in connection with proposed settlement, expects to record receivable of about $25.0 million from insurance carriers in Q2 2017.  Full Article

Clovis Oncology Q1 loss per share $1.33
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Clovis Oncology Inc ::Clovis Oncology announces first quarter 2017 operating results.Q1 loss per share $1.33.Q1 earnings per share view $-1.48 -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test
Thursday, 27 Apr 2017 07:05am EDT 

April 27 (Reuters) - Myriad Genetics Inc ::Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment.Says financial terms of deal were not disclosed..Myriad genetics inc- under deal,myriad will submit supplementary premarket approval application for bracanalysis cdx to include rubraca.  Full Article

Clovis Oncology Q4 loss per share $1.83
Wednesday, 22 Feb 2017 04:05pm EST 

Clovis Oncology Inc : Clovis Oncology announces 2016 operating results . Q4 loss per share $1.83 . Q4 earnings per share view $-1.64 -- Thomson Reuters I/B/E/S .Clovis Oncology Inc says Rucaparib MAA submission accepted and under review; CHMP opinion anticipated Q4 2017.  Full Article

BRIEF-Clovis Announces Priority Review Designation For Rucaparib Supplemental NDA

* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION